Tyrosine kinase inhibitors as novel drugs for the treatment of diabetes

Author: Prada Patricia O  

Publisher: Informa Healthcare

ISSN: 1354-3784

Source: Expert Opinion on Investigational Drugs, Vol.22, Iss.6, 2013-09, pp. : 751-763

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Introduction: Some inhibitors of tyrosine kinase, as imatinib, erlotinib and sunitinib have antihyperglycemic effects but the mechanisms are not totally clear. Areas covered: It is well established that insulin resistance and beta-cell failure are hallmarks of type 2 diabetes mellitus (DM2). The present review will discuss the molecular mechanisms that account for insulin resistance and beta-cell failure in DM2, and also the effect of tyrosine kinase inhibitors in these processes. Expert opinion: A better understanding of how these drugs improve the two most important mechanisms of DM2 associated with suggestions of clinical studies will lead to improve the treatment of this disease.